The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Recruiting
Phase 2
Interventional Study
Pleural Mesothelioma
Pleural Diseases
Cancer
FAPI
Fibroblast Activation Protein Inhibitor
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 70 (estimated)
- Sponsor
- Aalborg University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging.
The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT). The diagnostic accuracy will be determined with histopathology as reference standard.
For patients undergoing anticancer treatment (…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy.
* Undergone/undergoing FDG PET/CT as part of the diagnostic workup of a suspicious PM lesion.
* Considered physically and mentally able to participate in the research project.
* Un…
Contacts